Infantile neuronal ceroid lipofuscinosis

Infantile neuronal ceroid lipofuscinosis
[[File:|250px|alt=|]]
Synonyms	N/A
Pronounce
Field	N/A
Symptoms
Complications
Onset
Duration
Types
Causes
Risks
Diagnosis
Differential diagnosis
Prevention
Treatment
Medication
Prognosis
Frequency
Deaths

Infantile neuronal ceroid lipofuscinoses (INCL) or Santavuori disease or Hagberg-Santavuori disease or Santavuori-Haltia disease or Infantile Finnish type neuronal ceroid lipofuscinosis or Balkan disease is a form of NCL and inherited as a recessive autosomal genetic trait. The disorder is progressive, degenerative and fatal, extremely rare worldwide – with approximately 60 official cases reported by 1982, perhaps 100 sufferers in total today

– but relatively common in Finland due to the local founder effect.

Presentation

The development of children born with INCL is normal for the first 8–18 months, but will then flounder and start to regress both physically and mentally. Motor skills and speech are lost, and optic atrophy causes blindness. A variety of neurological symptoms, such as epilepsy and myoclonic seizures, appear. The senses of hearing and touch remain unaffected. The average lifespan of an INCL child is 9–11 years.

Causes

It has been associated with palmitoyl-protein thioesterase.

Treatment

Treatment is limited. Drugs can alleviate the symptoms, such as sleep difficulties and epilepsy. Physiotherapy helps affected children retain the ability to remain upright for as long as possible, and prevents some of the pain.

Recent attempts to treat INCL with cystagon have been unsuccessful.

See also

• FAIDD (The Finnish Association on Intellectual and Developmental Disabilities)

External links

Classification	ICD-10: E75.4 OMIM: 256730 MeSH: D009472 DiseasesDB: 31533
External resources

• GeneReviews/NCBI/NIH/UW entry on Neuronal Ceroid-Lipofuscinosis
• An overview (in Finnish)
• The INCL organization of Finland (in Finnish)